Tilray, Inc. Series 2 Stock News

I believe Tilray's rally mainly hangs on Schedule III hype. I see limited direct benefit for Tilray from Schedule III, as its U.S. exposure is mainly beer and beverage, not cannabis. Momentum and insider buying are positive, but slow revenue growth and a high P/E make me cautious about chasing the stock now.

Key Points in This Article: Cannabis stocks surged in 2018-2019 on federal legalization hopes but crashed as progress stalled.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands.

Tilray Affirms Continued Commitment to German Healthcare and Expanding Patient and Pharmacy Access in Europe's Largest Medical Cannabis Market Tilray Affirms Continued Commitment to German Healthcare and Expanding Patient and Pharmacy Access in Europe's Largest Medical Cannabis Market

NEW YORK and LEAMINGTON, Ontario, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today announced that it received written notice from the Nasdaq Stock Market, LLC (“Nasdaq”) confirming that Tilray is again in compliance with ...

Investors are closely watching the US cannabis space after President Donald Trump signaled plans to reschedule marijuana, a move that is expected to unlock near-term financial relief and longer-term growth for the industry. Trump recently stated that his administration will “be moving forward soon with rescheduling marijuana,” referring to its reclassification as a lower-risk Schedule III drug.

Tilray stock price continued its strong bull run this month, surging to a high of $1.46, its highest level since January and 305% from its lowest point this year. This surge has brought its market capitalization to over $1.53 billion, up from the year-to-date low of $350 million.

Tilray Brands (NASDAQ:TLRY) shares continued to gain momentum on Tuesday after the cannabis firm saw its price target boosted by Jefferies analysts. The analysts, who maintained a ‘Buy' rating on Tilray, upped their price target to $2 from $1.50, citing growing optimism about a potential shift in US federal cannabis policy.